REGENXBIO Inc. (RGNX)
| Bid | 7.5 |
| Market Cap | 392.68M |
| Revenue (ttm) | 82.04M |
| Net Income (ttm) | -223.6M |
| EPS (ttm) | -4.59 |
| PE Ratio (ttm) | -1.71 |
| Forward PE | -12.72 |
| Analyst | Buy |
| Ask | 7.92 |
| Volume | 334,770 |
| Avg. Volume (20D) | 1,108,559.3 |
| Open | 7.90 |
| Previous Close | 7.91 |
| Day's Range | 7.70 - 7.96 |
| 52-Week Range | 5.62 - 21.57 |
| Beta | 1.35 |
About RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, wh...
Analyst Forecast
According to 8 analyst ratings, the average rating for RGNX stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 308.16% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025. Partnership established with Nippon Shinyaku to develop RGX-121 and RGX-111 f...
